Genital Warts
📧 Sign up to get email alerts when something new happens for Genital Warts.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-03-06FDA Approved: IMIQUIMOD — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's generic imiquimod 5% cream (ANDA 201994) as an original application, expanding access to the dermatology indications…
-
FDA label_change · 2012-02-14FDA Approved: ZYCLARA — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for ZYCLARA (imiquimod) to update the labeling with new or expanded indications.
-
CLINICAL_TRIALS research · 2011-12-01Clinical Trial Update: Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile
A clinical trial update studying the epidemiology, costs, and psychosocial consequences of genital warts in Valparaiso, Chile.
-
CLINICAL_TRIALS trial_result · 2011-09-08Clinical Trial Update: Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil [NA]
This clinical trial update reports immunogenicity and reactogenicity data for alternative dosing schedules of Gardasil, the HPV vaccine; res…
-
CLINICAL_TRIALS trial_result · 2011-07-20Clinical Trial Update: Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts [Phase 3]
Phase 3 trial evaluating imiquimod cream for external genital warts has completed and posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-06-21Clinical Trial Update: Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) [Phase 1]
Phase 1 dose-escalation study of Merck's Broad Spectrum HPV Vaccine (V502-002) completed. Results were posted in 2011 and evaluated safety a…
-
CLINICAL_TRIALS trial_result · 2011-05-18Clinical Trial Update: Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts [Phase 3]
Phase 3 clinical trial update evaluating the safety and effectiveness of imiquimod cream for external genital warts. The study results were …
-
CLINICAL_TRIALS trial_result · 2010-09-08Clinical Trial Update: Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage [Phase 4]
Phase IV pharmacokinetic study comparing topically applied Veregen 15% with oral green tea intake to assess systemic exposure.
-
CLINICAL_TRIALS trial_result · 2010-08-09Clinical Trial Update: Anogenital Wart Burden and Cost of Illnesses
A completed clinical trial assessing the burden of anogenital warts and related costs of illness, conducted by Mahidol University.
-
CLINICAL_TRIALS trial_result · 2010-08-03Clinical Trial Update: Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) [Phase 2]
A Phase 2 dose-ranging study of a quadrivalent HPV vaccine (types 6, 11, 16, 18) labeled V501-007 was completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2010-03-08Clinical Trial Update: Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) [Phase 3]
Phase 3 trial of Gardasil (V501-016) in pre-adolescents and adolescents completed, with results posted in 2010, assessing prevention of cerv…
-
CLINICAL_TRIALS trial_result · 2010-02-01Clinical Trial Update: A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) [Phase 3]
A Phase 3 study evaluating Gardasil (qHPV) in mid-adult women to assess safety, immune response, and efficacy; the trial is completed and re…
-
CLINICAL_TRIALS trial_result · 2009-11-26Clinical Trial Update: Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) [Phase 3]
Phase 3 clinical trial update for Gardasil evaluating prevention of cervical cancer and genital warts; the study has been completed and resu…
-
CLINICAL_TRIALS trial_result · 2009-11-25Clinical Trial Update: Low Dose Cyclophosphamide Treats Genital Warts [Phase 3]
Phase 3 trial evaluating low-dose cyclophosphamide for genital warts has completed. The update does not provide efficacy results in the snip…
-
CLINICAL_TRIALS trial_result · 2009-11-20Clinical Trial Update: Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) [Phase 3]
Phase 3 trial evaluating Gardasil's efficacy against cervical intraepithelial neoplasia lesions and genital warts in women; completed with r…
-
CLINICAL_TRIALS trial_result · 2009-07-13Clinical Trial Update: Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) [Phase 3]
Phase 3 trial evaluating the safety of administering Gardasil concurrently with a combined Diphtheria/Tetanus/Pertussis vaccine and a Mening…
-
CLINICAL_TRIALS trial_result · 2009-04-09Clinical Trial Update: Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts [Phase 1]
This update reports on a Phase 1 safety and preliminary effectiveness study of GS-9191, an experimental topical ointment, for the treatment …
-
EMA guidance · 2009-02-19European Medicines Agency recommends continued vaccination with Gardasil
The EMA recommends continuing vaccination with Gardasil, endorsing ongoing use of the HPV vaccine for protection against HPV-related disease…
-
FDA approval · 2008-09-18FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VEREGEN (sinecatechins) submitted by ANI Pharmaceuticals, Inc., for the product.
-
FDA approval · 2007-12-19FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VEREGEN (sinecatechins) filed by ANI Pharmaceuticals, Inc.
-
FDA approval · 2007-06-27FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Veregen (sinecatechin) submitted by ANI Pharmaceuticals.
-
FDA approval · 2007-06-01FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VEREGEN (sinecatechins) by ANI Pharmaceuticals, signaling regulatory action on the product.
-
FDA approval · 2006-10-31FDA Approved: VEREGEN — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved Veregen (sinecatechins) topical ointment under its original NDA for the treatment of external genital warts.